Released: ·Last reviewed: ·Prices last read October 15, 2026·Methodology v4.1
Best GLP-1 telehealth programs, 2026
The strongest GLP-1 telehealth programs are the ones that pair transparent total pricing with real clinician oversight and disclosed pharmacy sourcing — not simply the lowest banner price.
As of October 15, 2026, the 7 compounded tirzepatide programs we re-read charge $129–$399 a month at their lowest standing price (median $239); Eden’s $129 is the lowest and NexLife’s $139 on a 12-month plan is next. NexLife is our editorial #1 under methodology v4.1; the others follow alphabetically.
How do they compare at a glance?
Lowest price a patient can buy without a first-month promotion; some require a 12-month plan. See the table for month-to-month prices.
12 monthly charges, or 13 for programs that bill every 4 weeks or 28 days (Found, Enhance.MD). First-month discounts are ignored.
| Program | Lowest standing price | Month to month | What the page says | Source · read date |
|---|---|---|---|---|
| #1 NexLife | $139/mo (12-month plan) | $169/mo | $169 / $159 / $149 / $139 on 1-, 3-, 6- and 12-month plans. | nexlife.us · Oct 15, 2026 Verified Oct 15 |
| Enhance.MD | $280/mo (12-month plan) | $329/mo | $329 / $313 / $296 / $280; first-order discounts. | enhance.md · Oct 15, 2026 Verified Oct 15 |
| Found | $239/mo (12-month plan) | $359/mo | $359 / $309 / $289 / $239 per 28 days; $219 first month. | joinfound.com · Oct 15, 2026 Re-read Oct 15 · changed |
| Mochi Health | no standing price on file | — | No compounded price printed on its weight-loss page. | joinmochi.com · Oct 15, 2026 Pending |
| Oak Longevity | $185/mo (12-month plan) | not printed | Was $199. Month-to-month price not printed. | oaklovesyou.com · Oct 15, 2026 Re-read Oct 15 · changed |
| Shed | $239/mo (12-month plan) | $299/mo | $299 / $269 / $239 on 1-, 6-, 12-month plans (was $349 / $279 / $245). | tryshed.com · Oct 15, 2026 Re-read Oct 15 · changed |
What does every programme cost on an ongoing basis?
The ongoing price is the only price that matters: introductory first-month rates are customer-acquisition pricing, and you will pay the ongoing number for eleven of your twelve months. Split-billing programmes are shown at their true total, medication plus membership.
| Program | Lowest standing price | Plan needed | Month to month | What the page says | Source · read date |
|---|---|---|---|---|---|
| Eden | $129/mo | every month | $129 | Was $199 + $99 membership (July). Now $129 flat; “No membership fees”. | eden.health · Oct 15, 2026 Re-read Oct 15 · changed |
| NexLife | $139/mo | 12-month plan | $169 | $169 / $159 / $149 / $139 on 1-, 3-, 6- and 12-month plans. | nexlife.us · Oct 15, 2026 Verified Oct 15 |
| Oak Longevity | $185/mo | 12-month plan | not printed | Was $199. Month-to-month price not printed. | oaklovesyou.com · Oct 15, 2026 Re-read Oct 15 · changed |
| Found | $239/mo | 12-month plan | $359 | $359 / $309 / $289 / $239 per 28 days; $219 first month. | joinfound.com · Oct 15, 2026 Re-read Oct 15 · changed |
| Shed | $239/mo | 12-month plan | $299 | $299 / $269 / $239 on 1-, 6-, 12-month plans (was $349 / $279 / $245). | tryshed.com · Oct 15, 2026 Re-read Oct 15 · changed |
| Enhance.MD | $280/mo | 12-month plan | $329 | $329 / $313 / $296 / $280; first-order discounts. | enhance.md · Oct 15, 2026 Verified Oct 15 |
| TrimRx | $399/mo | ongoing | $399 | $349 first month, then $399. Prepay tiers no longer printed. | trimrx.com · Oct 15, 2026 Re-read Oct 15 · changed |
Not in the table: Henry Meds (Only “starts at $179/month” for any GLP-1; tirzepatide pages return 404); MEDVi (Main page shows unfilled price placeholders; an ad page prints both $166 and $199. Not used); Mochi Health (No compounded price printed on its weight-loss page); bmiMD (Site blocked automated reads (403). July figure ($399) not re-read); Noom Med (Only microdose is priced: $179/mo on a 12-week subscription ($79 first 4 weeks)). Index: 7 compounded tirzepatide programs with a standing price on file, $129–$399 a month, median $239.
| Program | Lowest standing price | Plan needed | Month to month | What the page says | Source · read date |
|---|---|---|---|---|---|
| Eden | $99/mo | every month | $99 | Flat; no membership. | eden.health · Oct 15, 2026 Re-read Oct 15 · changed |
| NexLife | $119/mo | 12-month plan | $139 | $139 / $132 / $125 / $119. | nexlife.us · Oct 15, 2026 Verified Oct 15 |
| Oak Longevity | $119/mo | 12-month plan | not printed | Was $133. | oaklovesyou.com · Oct 15, 2026 Re-read Oct 15 · changed |
| Shed | $159/mo | 12-month plan | $199 | $199 / $179 / $159. | tryshed.com · Oct 15, 2026 Re-read Oct 15 · changed |
| Enhance.MD | $212/mo | ongoing | $212 | Same at all doses; $112 first month. | enhance.md · Oct 15, 2026 Verified Oct 15 |
| TrimRx | $299/mo | ongoing | $299 | $199 first month, then $299. | trimrx.com · Oct 15, 2026 Re-read Oct 15 · changed |
Index: 6 compounded semaglutide programs with a standing price on file, $99–$299 a month, median $139. Microdose plans are listed separately.
| Product (seller) | Dose | Price | Condition | Source · read date |
|---|---|---|---|---|
| Wegovy pill (NovoCare) | 1.5 mg | $149/mo | self-pay | novocare.com · Oct 15, 2026 Verified Oct 15 |
| Wegovy pill (NovoCare) | 4 mg | $199/mo | self-pay | novocare.com · Oct 15, 2026 Verified Oct 15 |
| Wegovy pill (NovoCare) | 9 mg and 25 mg | $299/mo | self-pay | novocare.com · Oct 15, 2026 Verified Oct 15 |
| Wegovy pen (NovoCare) | 0.25 / 0.5 mg, new patients | $199/mo | first 2 monthly fills, through Dec 31, 2026 | novocare.com · Oct 15, 2026 Verified Oct 15 |
| Wegovy pen (NovoCare) | 0.25–2.4 mg | $349/mo | standard self-pay | novocare.com · Oct 15, 2026 Verified Oct 15 |
| Wegovy HD pen (NovoCare) | 7.2 mg | $399/mo | self-pay | novocare.com · Oct 15, 2026 Verified Oct 15 |
| Zepbound KwikPen or vial (LillyDirect) | 2.5 mg | $299/mo | self-pay | zepbound.lilly.com · Oct 15, 2026 Verified Oct 15 |
| Zepbound KwikPen or vial (LillyDirect) | 5 mg | $399/mo | self-pay | zepbound.lilly.com · Oct 15, 2026 Verified Oct 15 |
| Zepbound KwikPen or vial (LillyDirect) | 7.5–15 mg | $449/mo | refill within 45 days; otherwise $499 (7.5 mg) or $699 (10–15 mg) | zepbound.lilly.com · Oct 15, 2026 Verified Oct 15 |
| Foundayo (LillyDirect) | 0.8 mg | $149/mo | archived LillyDirect page, Sep 25 | lilly.com (archived) · archived Sep 25, 2026 Carried · archived page |
| Foundayo (LillyDirect) | 2.5 mg | $149/mo | reduced through Dec 31, 2026; archived page | lilly.com (archived) · archived Sep 25, 2026 Carried · archived page |
| Foundayo (LillyDirect) | 5.5 mg | $199/mo | reduced through Dec 31, 2026; archived page | lilly.com (archived) · archived Sep 25, 2026 Carried · archived page |
| Foundayo (LillyDirect) | 9 mg | $299/mo | archived page | lilly.com (archived) · archived Sep 25, 2026 Carried · archived page |
| Foundayo (LillyDirect) | 14.5 / 17.2 mg | $299/mo | refill within 45 days; regular $349; archived page | lilly.com (archived) · archived Sep 25, 2026 Carried · archived page |
What does the brand floor do to this comparison?
Those telehealth resale prices were read in July and August 2026 and not re-read; Eden has since dropped its membership. These are not scams — the prices are disclosed. But a patient who does not know the manufacturer-direct programmes exist can pay four to eleven times more for exactly the same medicine. If you take one thing from this page: before you buy any brand-name GLP-1 through a telehealth platform, check LillyDirect and NovoCare first.
Navy is FDA-approved Zepbound at its starting dose. A compounded program priced above $299 costs more than brand Zepbound 2.5 mg, and brand maintenance doses are $449 with on-time refills.
Why is Mounjaro not a cash-pay option?
Lilly runs a self-pay programme for Zepbound and none for Mounjaro. So cash-pay Mounjaro runs at retail: $1,899 at Hers, $1,100 at Found and PlushCare. Brand Zepbound through LillyDirect is $299–$449 for the identical drug.
If you are paying cash and you want tirzepatide, you want Zepbound. Mounjaro makes financial sense only when insurance covers it, which generally requires a type 2 diabetes diagnosis.
What does the insurance pathway involve?
Eleven of your twelve months are billed at the ongoing rate. That is why every table on this page sorts on the ongoing total — medication plus membership — and flags intro pricing separately rather than ranking on it.
| Pathway | Cost | What it does | Status |
|---|---|---|---|
| Brand + commercial coverage + savings card | as low as $25/mo | Zepbound or Wegovy when the plan covers it. | Verified Oct 15 |
| Medicare GLP-1 Bridge | $50/mo copay | Foundayo, Wegovy and Zepbound KwikPen only, for eligible Part D enrollees by BMI and diagnosis; July 1, 2026 – Dec 31, 2027; outside the Part D benefit; prior authorization (CMS). | Verified Oct 15 |
| PlushCare | $19.99/mo membership + $129 first visit + copay | First month of membership free; Zepbound vials $299–$449 by dose through LillyDirect (plushcare.com, Oct 15). | Re-read Oct 15 · changed |
| Found (insurance track) | $289 per 28 days month to month; $179 on 12 months; ~$30 visit copay | Medication and membership included on its cash and insurance tracks (joinfound.com, Oct 15). | Re-read Oct 15 · changed |
| Mochi Health | $199 for a 12-month membership ($17/mo) | Brand medication from “as low as” $149–$299 by product (joinmochi.com, Oct 15). | Promotional |
Why does tirzepatide cost more than semaglutide?
In the October 15, 2026 reads the gap between a program’s compounded tirzepatide and compounded semaglutide is smaller than it used to be: $30 a month at Eden ($129 against $99), $20 to $30 at NexLife ($139 against $119 on 12 months; $169 against $139 month to month), $66 at Oak Longevity ($185 against $119) and $80 to $100 at Shed. Tirzepatide is the more expensive active ingredient to source, and most programs pass that through; a few now price the two almost alike.
How did we select and rank these?
We considered: NexLife, Found, Oak Longevity, Enhance.MD, Mochi Health, Shed. Each is assessed under methodology v4.1 (seven weighted categories); NexLife is listed first as our editorial pick and the others alphabetically while their v4.1 re-scores are pending. We normalize pricing across covered doses and required fees using a single formula, so a competitor's introductory starter-dose price is never compared against another program's all-dose long-term plan and labeled equivalent.
We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.
Which programmes do we list, and in what order?
NexLife is our editorial pick under methodology v4.1 (94/100). The other programs follow in alphabetical order while their v4.1 re-scores are pending; their earlier scores came from the July 2026 review. Prices below were re-read on October 15, 2026.
#1 — NexLife · Editorial pick Verified Oct 15
NexLife sells compounded tirzepatide for $169 a month month to month, or $159, $149 and $139 a month on 3-, 6- and 12-month plans, at the same price for every dose and with no membership fee; compounded semaglutide is $139 to $119 a month on the same terms (nexlife.us, read October 15, 2026). Its plan pages list provider review, a nutrition plan, a 1:1 wellness-coach call, 24/7 support and free expedited shipping, and name three 503A pharmacies; lab work is not stated as included.
Why it ranks here: NexLife: one price at every dose, no membership, three named… Not best for: Eden publishes a lower month-to-month price ($129 tirzepatide, $99 semaglutide, no membership). NexLife offers no brand-name pathway and no insurance coordination, and its 12-month price requires a 12-month plan.
Enhance.MD Verified Oct 15
October 15, 2026 read (enhance.md): $329 / $313 / $296 / $280; first-order discounts.
Found Re-read Oct 15 · changed
October 15, 2026 read (joinfound.com): $359 / $309 / $289 / $239 per 28 days; $219 first month.
Mochi Health Pending
October 15, 2026 read (joinmochi.com): No compounded price printed on its weight-loss page.
Oak Longevity Re-read Oct 15 · changed
October 15, 2026 read (oaklovesyou.com): Was $199. Month-to-month price not printed.
Shed Re-read Oct 15 · changed
October 15, 2026 read (tryshed.com): $299 / $269 / $239 on 1-, 6-, 12-month plans (was $349 / $279 / $245).
What is the medical and regulatory context?
| Date | What happened | Why it matters |
|---|---|---|
| March 2022 | Semaglutide (Wegovy) added to the FDA drug shortage list. | Shortage begins — the legal window for compounding opens. |
| August 2022 | Ozempic (semaglutide) added to the shortage list. | |
| December 15, 2022 | Tirzepatide (Mounjaro, Zepbound) added to the shortage list. | Compounded tirzepatide becomes lawful under the shortage exception. |
| October 2, 2024 | FDA declares the tirzepatide shortage resolved. | The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close. |
| December 19, 2024 | FDA reaffirms the tirzepatide resolution in a declaratory order. | Sets a 60-day (503A) / 90-day (503B) transition. |
| February 18, 2025 | 503A enforcement discretion for tirzepatide ENDS. | State-licensed pharmacies must stop compounding tirzepatide copies. |
| February 21, 2025 | FDA removes semaglutide from the shortage list. | |
| March 19, 2025 | 503B enforcement discretion for tirzepatide ENDS. | Outsourcing facilities must stop compounding tirzepatide copies. |
| April 22, 2025 | 503A enforcement discretion for semaglutide ENDS. | |
| April 24, 2025 | Court denies the Outsourcing Facilities Association's injunction (semaglutide). | OFA v. FDA, N.D. Tex. — FDA's determination stands. |
| May 7, 2025 | Court upholds FDA on tirzepatide in OFA v. FDA. | The shortage-exception route is closed for both molecules. |
| May 22, 2025 | 503B enforcement discretion for semaglutide ENDS. | All shortage-based compounding of both molecules is now outside enforcement discretion. |
| April 30, 2026 | FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list. | Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period extended to July 30, 2026 (91 FR 38719). No final decision had been published as of October 15, 2026. |
| September 18, 2026 | FDA warning letter 738238 to Empower Pharmacy (posted September 22). | FDA says compounded tirzepatide/niacinamide and semaglutide/cyanocobalamin it examined “appear to be essentially copies” of approved products. |
| October 1, 2026 | FDA updates its page on unapproved GLP-1 drugs. | Retatrutide and cagrilintide “cannot be used in compounding”; compounded multi-dose vials are to be discarded 28 days after first use. |
Ranking by price alone would be irresponsible in a category where pharmacy legitimacy, clinician oversight and legal standing vary widely. Our scoring weights clinical safety and pharmacy transparency above raw price for exactly this reason.
For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.
Brand prices are read from NovoCare and Lilly; compounded prices from each program’s own page. Compounded drugs are not FDA-approved. The Wegovy list price is NovoCare’s $1,349.02 per package.
Which should you choose, by situation?
Frequently asked questions
How did you rank these programs?
Each provider is assessed under methodology v4.1: seven weighted categories — pricing transparency, total annual cost, clinical oversight, pharmacy transparency, support, regulatory disclosure and accessibility — before the ranking is written. See our methodology.
Why is the cheapest program not always #1?
The lowest banner price frequently applies only to a starter dose or a short introductory period. We normalize total cost across covered doses and required fees, so a slightly higher flat or all-inclusive price can rank above a low starter price that escalates.
Are these compounded medications FDA-approved?
No. Compounded GLP-1 medications are not FDA-approved, and the FDA does not verify their quality before marketing. Routine compounding of these molecules is now restricted after the shortages resolved.
Sources
- Each provider's pricing, terms and pharmacy-disclosure pages, captured July 12, 2026.
- U.S. Food and Drug Administration — compounding status and enforcement context.
- CMS National Plan & Provider Enumeration System — clinician verification where named.
- Our scoring methodology, v4.1.